32 −3.2 ± 7.4 −3.0 ± 8.3 13.44 ± 3.22 1.3 ± 6.2 1.8 ± 6.1 Inter-trochanter Cortical thickness (mm) 1.43 ± 0.26 0.9 ± 5.9 0.7 ± 6.4 1.51 ± 0.29 https://www.selleckchem.com/products/torin-2.html −2.3 ± 6.6 −0.8 ± 7.7 Cortical CSA (cm2) 1.38 ± 0.29 3.8 ± 7.4* 2.9 ± 8.6 1.54 ± 0.33 −1.6 ± 5.6 −0.6 ± 5.5 Total CSA (cm2) 2.38 ± 0.45 3.8 ± 8.8* 4.7 ± 9.4* 2.59 ± 0.5 −1.8 ± 5.6 −0.6 ± 4.8 Cortical perimeter (cm) 16.76 ± 1.15 0.2 ± 3.3 −0.6 ± 2.0 17.12 ± 1.18 0.6 ± 2.4 0.0 ± 2.1 Cortical vBMD (mg/cm3) 638.96 ± 48.01 −0.4 ± 2.4 −1.5 ± 2.1** 646.03 ± 44.09 −0.3 ± 2.9 −0.6 ± 2.4 Total vBMD (mg/cm3) 186.13 ± 35.97 1.1 ± 3.3 0.7 ± 4.7 196.1 ± 35.7 −1.5 ± 4.5
−1.5 ± 4.8 SM (cm3) 0.67 ± 0.18 5.0 ± 15.8 4.1 ± 11.8 0.73 ± 0.18 2.4 ± 12.0 1.8 ± 10.2 BR 19.71 ± 3.6 2.1 ± 10.2 1.8 ± 10.7 19.26 ± 4.41 4.3 ± 9.5* 2.1 ± 10.1 Femoral shaft Cortical thickness (mm) 3.71 ± 0.62 0.7 ± 5.1 2.6 ± 4.5* 3.91 ± 0.62 −0.7 ± 4.6 −1.3 ± 3.9 Cortical CSA (cm2) 2.22 ± 0.39 1.7 ± 5.2 2.7 ± 3.6* 2.35 ± 0.39 −0.6 ± 4.1 −0.5 ± 3.0 Total CSA (cm2) 2.38 ± 0.38 1.7 ± 5.0 2.5 ± 3.4* 2.5 ± 0.39 −0.5 ± 4.0 −0.1 ± 3.0
Cortical perimeter (cm) 10.27 ± 0.6 0.4 ± 3.8 −0.7 ± 2.5 10.3 ± 0.7 0.2 ± 4.3 0.5 ± 3.2 Cortical vBMD (mg/cm3) 879.65 ± 70.77 0.4 ± 2.7 0.1 ± 3.6 892.97 ± 59.03 0.3 ± 4.1 −0.9 ± 3.1 Total vBMD (mg/cm3) 461.36 ± 77.37 0.7 ± 5.1 1.1 ± 5.7 482.05 ± 74.95 −0.2 ± 5.2 −1.4 ± 4.3 SM (cm3) 0.88 ± 0.18 1.3 ± 5.9 2.7 ± 7.2 0.93 ± 0.2 ISRIB in vivo −0.8 ± 5.2 0.3 ± 4.8 BR 3.67 ± 0.88 −0.4 ± 7.7 −3.3 ± 5.4* 3.39 ± 0.75 0.9 ± 6.7 1.9 ± 5.3 Data are mean ± SD QCT quantitated computed tomography, CSA cross-sectional area, vBMD volumetric bone mineral density, Mannose-binding protein-associated serine protease SM section modulus, BR buckling ratio * p < 0.05; ** p < 0.01 compared with baseline Effect of teriparatide on cortical thickness, cortical and total CSA, and cortical perimeter compared to placebo Comparisons of cortical thickness, CSA, and perimeter between the two groups are shown in Fig. 1. Significantly higher cortical thickness was OSI-744 price observed in the teriparatide group at the femoral neck (48 and 72 weeks) and shaft
(72 weeks) (Fig. 1a).